Androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC) patients, received enzalutamide or abiraterone. The gene discussed is AR; the disease is prostate carcinoma.